VIM and glioblastoma: Regarding the mechanism of action for anti-cell-surface VIM therapies, it appears that CSCs have more cell-surface VIM expression, as most cell-surface VIM-expressing cells also expressed the glioblastoma CSC markers, CD133 or CD44 [131].